On Wednesday August, 15, Senesco Technologies, Inc. announced the results of their Phase 1a/2b Multiple Myeloma Trial and were given the green light to increase dosing in the next group of patients. Manufactured by VGXI for Senesco, SNS01-T is designed to treat multiple myeloma, a type of cancer that starts in the body’s plasma cells inside of the bone marrow. The antibody producing plasma cells in multiple myeloma patients grow uncontrollably, causing tumors to grow in solid bone tissue. The tumors interrupt the bone marrow’s ability to produce normal, healthy blood cells and platelets, making it increasingly difficult for patients with multiple myeloma to fight off infections and form proper blood clots to reduce bleeding, especially as the disease progresses. Answering the call for a novel treatment for this incurable disease, SNS01-T was recently evaluated in a small clinical trial consisting of 6 initial relapsed or refractory multiple myeloma patients. By the end of the trial, the 3 remaining patients (3 were removed from the trial by their physicians) were reported to have experienced no adverse effects from the drug. The determination was made following an observation period that reported SNS01-T to be safe and well tolerated. SNS01-T also met the criteria for Stable Disease in 2 of the 3 patients. “The promising result that we observed in the first patient has been confirmed by a similar effect, Stable Disease, in another patient. We are looking forward to seeing the effect of increasing the dose level in the next group of patients” stated Harlan Waksal, M.D., Chairman of Senesco. At this stage in the clinical trial, it appears that SNS01-T could be a viable treatment for multiple myeloma. The results from the next cohort of the study should be available by the end of 2012 and will assess the effects of SNS01-T on tumor response and time relapse and, ultimately, whether the drug is well tolerated and can be administered safely to a larger number of patients. If you or someone you know is suffering from relapsed or refractory multiple myeloma, Senesco is currently enrolling for the next cohort of their SNS01-T clinical trial. You can see the details and find out more on the national clinical trials website.